Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05922124 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii

Study acronym: CASCADE
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 1, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 30, 2024 to Sep 1, 2024
    • Study sites: 0 to 3
    v6
  2. Primary completion date: Jul 2025 to Jul 2026
    • Start date: Apr 1, 2024 to May 30, 2024
    • Study completion date: Sep 2025 to Sep 2026
    v5
  3. Start date: Jan 2024 to Apr 1, 2024v4
  4. Start date: Sep 2023 to Jan 2024
    • Primary completion date: Jan 2025 to Jul 2025
    • Study completion date: Feb 2025 to Sep 2025
    v3
  5. Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 4 of 9 entries
    • Study description expanded, about 3 words
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Patients with bloodstream infections, hospital acquired pneumonia or ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) treated with cefiderocol combined with ampicillin sulbactam will be compared to patients treated treated with colistin alone or colistin combined with meropenem.
Trial Details
NCT Number NCT05922124
Lead Sponsor Rambam Health Care Campus
Collaborators: Monaldi Hospital, Rutgers Robert Wood Johnson Medical School, Pisa University Hospital, Assaf-Harofeh Medical Center, Sheba Medical Center
Conditions
(from sponsor)		 Carbapenem Resistant Bacterial Infection, Acinetobacter Bacteremia, Acinetobacter Pneumonia
Enrollment 734 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov